Wellington Management Group LLP Buys 7,645 Shares of Dianthus Therapeutics, Inc. $DNTH

Wellington Management Group LLP increased its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,982 shares of the company’s stock after acquiring an additional 7,645 shares during the quarter. Wellington Management Group LLP owned about 0.21% of Dianthus Therapeutics worth $1,233,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DNTH. JPMorgan Chase & Co. boosted its position in shares of Dianthus Therapeutics by 14.0% during the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company’s stock worth $264,000 after acquiring an additional 1,490 shares during the last quarter. Invesco Ltd. boosted its position in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock worth $251,000 after acquiring an additional 790 shares during the last quarter. Barclays PLC boosted its position in shares of Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after acquiring an additional 1,082 shares during the last quarter. MetLife Investment Management LLC lifted its position in Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after purchasing an additional 433 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Dianthus Therapeutics by 21.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company’s stock valued at $207,000 after purchasing an additional 1,647 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wedbush increased their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, Robert W. Baird lowered their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.00.

Dianthus Therapeutics Trading Down 5.0%

Shares of DNTH opened at $23.57 on Monday. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $32.27. The company has a market cap of $758.72 million, a P/E ratio of -7.25 and a beta of 1.46. The company’s fifty day simple moving average is $20.60 and its 200-day simple moving average is $20.01.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.87 million. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.